Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli

a technology of pulmonary alveoli and clarithromycin, which is applied in the direction of biocide, drug composition, animal husbandry, etc., can solve the problems of reducing the gas exchange efficiency and the elastic recoil of the whole lung, reducing pulmonary functions, and not being able to alleviate the destruction of pulmonary alveoli, so as to retard the progression of pulmonary emphysema. itself, and the effect of reducing the pulmonary function

Inactive Publication Date: 2006-12-28
TAISHO PHARMACEUTICAL CO LTD
View PDF16 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017] According to this invention, it has been demonstrated that clarithromycin or a salt thereof is effective as a therapeutic or prophylactic agent for a pulmonary disorder caused by the destruction of pulmonary alveoli.

Problems solved by technology

Pulmonary emphysema reduces gas exchange efficiency and the elastic recoil of the whole lung, and it eventually lowers pulmonary functions.
However, they have not been able to alleviate the destruction of pulmonary alveoli and to retard the progression of the pulmonary emphysema itself.
It has, however, been reported that they are ineffective against the pulmonary emphysema itself.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli
  • Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0029]

clarithromycin50mglactose40mgcorn starch49.75mgcrystalline cellulose17mgcarmellose calcium17mghydroxypropyl cellulose5.25mgmagnesium stearate1mgtotal180mg

[0030] Clarithromycin, lactose, corn starch, crystalline cellulose, and carmellose calcium were uniformly mixed. To this was added a 10% hydroxypropyl cellulose aqueous solution. After blending the mixture, the granules were dried and sieved with a 30M-screen to make uniform granules. Magnesium stearate was added to the granules and it was compressed to form tablets.

[0031] The pharmacological action of clarithromycin (improvement to a pulmonary emphysema condition) will be next explained by way of test examples.

[0032] Test Example 1: Pharmacological Effect in Model Mice with Tobacco Smoke-Induced Pulmonary Emphysema

[0033] The model mice with tobacco smoke-induced pulmonary emphysema mimicking human pulmonary emphysema were constructed according to the method as described in Hautamaki, R. D. et al., Science 1997, 277:2002-2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
body weightaaaaaaaaaa
weightaaaaaaaaaa
weightaaaaaaaaaa
Login to view more

Abstract

For the purpose of treatment and / or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli resulting from smoking, air pollution, noxious gas, etc., there are provided, among others, a method of administering clarithromycin or a salt thereof to a mammal and a pharmaceutical composition comprising clarithromycin or a salt thereof.

Description

BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] This invention relates to the use of clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli. More particularly, it relates to a therapeutic or prophylactic agent comprising as an effective ingredient, clarithromycin or a salt thereof, a pharmaceutical composition comprising clarithromycin or a salt thereof, and a method of administering clarithromycin or a salt thereof to a mammal, for the purpose of such treatment or prevention, as well as to the use of clarithromycin or a salt thereof in the manufacture of a medicament. [0003] 2. Related Background Art [0004] The lung branches out from bronchi and is gradually subdivided finely to form the eventual baggy structures which are referred to as “alveoli (or alveolus)”. The alveolus is composed of alveolar epithelial cells, vascular cells, and extracellular matrices (such as elastin or colla...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7048
CPCA61K31/7048A61P11/00A61P43/00
Inventor TAKAYAMA, KIYOSHI
Owner TAISHO PHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap